CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Aims: The purpose of this study is to determine if it is possible to safely reduce the total number of cycles of chemotherapy needed for Hodgkin lymphoma based on the patient's response during treatment as seen on positron emission tomography (PET) scan images. A PET scan is an imaging technique that can detect the possibility of active cancer.
Diagnosis: Bulky Stage I and II Classical Hodgkin Lymphoma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-030
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 50604: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Non-Bulky Stage I and Stage II Hodgkin Lymphoma (HL)
Aims: The purpose of this clinical trial is to determine the effect of response-based treatment. In the study, the type treatment a patient receives for Hodgkin lymphoma is based on the response during therapy as seen on positron emission tomography (PET) scan images. A PET scan is an imaging technique that can detect the possibility of active cancer. Response to treatment may affect which type of chemotherapy a patient will receive and whether or not the patient will need radiation therapy.
Diagnosis: Non-Bulky Stage I and II Hodgkin Lymphoma
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH11-029
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
E2905: Randomized Phase III Trial Comparing The Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlemid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.
Aims: The purpose of this study is to compare the good and/or bad affects of a drug called lenalidomide on blood disorders when given alone or in combination with a drug called epoetin alfa. Epoetin alfa boosts the production of red blood cells. The drug lenalidomide makes young red blood cells more likely to be affected by the growth-promoting effects of epoetin alfa. This study aims to determine if the combination of treatment with epoetin alfa and lenalidomide is better than lenalidomide alone in improving red blood cell production and decreasing the need for blood transfusions in patients with MDS (myelodysplastic syndrome).
Diagnosis: Myelodysplastic Syndrome or Symptomatic Anemia
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH09-422
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
E3A05: Ancillary Laboratory Protocol For Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders.
Aims: This is a laboratory study where patients may decide to contribute samples of blood and bone marrow which will be used to screen them for participation in treatment studies and may be used for future research of plasma cells disorders. Patients may choose to only participate in the screening portion of this study.
Diagnosis: Plasma Cell Disorders
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH09-311
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
E3903: Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders.
Aims: The purpose of this study is to determine the genetic make-up of a patient's disease in order to confirm that the treatment received is the best available. Treatment for blood disorders depends on the type of blood/bone marrow cells that are affected. In this study, blood samples will be collected so that the doctor can make sure that treatment is appropriate for a specific disease. Also, researchers want to gather samples (extra blood and bone marrow) to be used for future research on blood disorders.
Diagnosis: Leukemia and Other Blood Disorders
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH05-385
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 9665: The CALGB Leukemia Tissue Bank
Aims: The purpose of this study is to collect blood and tissue samples from patients with leukemia and myelodysplasia for the purpose of future research. This research is being done to better understand the causes of leukemia and myelodysplasia and to develop improved methods of diagnosis and treatment for these diseases.
Diagnosis: Leukemia or Myelodysplasia
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH04-248
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 8461: Cytogenetic Studies in Acute Leukemia
Aims: The purpose of this study is to determine if response to treatment is related to particular leukemia cell types. Researchers want to obtain samples of blood and bone marrow from patients with Acute Leukemia and Multiple Myeloma to study certain characteristics in the chromosomes (genetic material) of cells affected by this disease.
Diagnosis: Acute Leukemia and/or Multiple Myeloma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH04-247
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 10404: A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
Aims: The purpose of this study is to find out the effects (good and bad) of treatment with four different therapies that include combinations of the drugs fludarabine, rituximab, cyclophosphamide, and lenalidomide. In addition, the study will look at differences between treatments for high risk and low risk (Chronic Lymphocytic Leukemia) CLL patients.
Diagnosis: Chronic Lymphocytic Leukemia
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH11-173
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
Merck 001-02: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Aims: Persons undergoing a transplant of blood-producing cells (autologous bone marrow or stem cell transplant) often have weakened immune systems. This makes them more susceptible to certain infections including the varicella-zoster virus, a virus that causes chicken pox and shingles. This research study will test an investigational vaccine, V212, aimed at preventing shingles.
Diagnosis: Patients undergoing an autologous bone marrow or stem cell transplant
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH11-062
Sponsor: Merck & Co., Inc.
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
TELESTO ICL670A2302: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Deferasirox in Patients with Myelodysplastic Syndromes (low/int-1 risk) and Transfusional Iron Overload (TELESTO)
Aims: Myelodysplastic Syndromes (MDS) are disorders of the bone marrow in which blood cells are not produced in sufficient quantities. MDS can cause anemia, or a decrease in the number of red blood cells, which usually is treated through the use of blood transfusions. However, in many patients, this leads to a build-up of iron in the body called secondary iron overload. Iron overload can lead to liver and heart damage. Deferasirox is an oral medicine used to treat iron overload due to blood transfusions and has been approved by the US Food and Drug Administration for this purpose. However, the benefit of excess iron removal with Deferasirox is not well established for patients with MDS. This study will evaluate patients with Myelodysplastic Syndrome who are treated with Deferasirox compared to MDS patients who take a placebo (pill that contains no medicine).
Diagnosis: Myelodysplastic Syndrome (MDS) patients who have had multiple blood transfusions
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-165
Sponsor: Novartis Pharmaceuticals
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumuamb, Bortezomib (NSC #681239, IND#58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
Aims: The purpose of this study is to compare the effects of treatment with a combination of the drugs ofatumumab and bendamustine against treatment with a combination of the drugs ofatumumab, bendamustine, and bortezomib in patients with follicular lymphoma. The combination of these drugs has not been approved for use in follicular lymphoma by the FDA. However, these drugs are FDA-approved for certain types of cancers when used individually.
Diagnosis: Follicular Lymphoma
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH12-075
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 20202: Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Aims: The purpose of this study is to examine acute myeloid leukemia (AML) cells and chromosomes, genes and proteins within these cells. This may help researchers learn more about how to prevent, find, and treat cancer and other diseases. In some instances, this study will be necessary to determine eligibility for treatment on a CALGB clinical trial.
Diagnosis: Acute Myeloid Leukemia
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH12-217
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 11002: A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients >60 Years Old with Acute Myeloid Leukemia (AML)
Aims: The standard chemotherapy treatment for Acute Myeloid Leukemia (AML) is not as successful in older patients; requiring prolonged hospitalization, it is often felt to be difficult for older patients. The purpose of this trial is to compare the effects, good and/or bad, of treatment using the drug decitabine alone with treatment using a combination of decitabine and another drug, bortezomib, in AML patients over the age of sixty. These treatments are lower intensity chemotherapy treatments than the standard chemotherapy treatment for AML. Researchers want to know if these experimental treatments are more successful in older adults than standard treatment.
Diagnosis: Acute Myeloid Leukemia
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH12-216
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes
CALGB 11001: A Phase II Study Incorporating Sorafenib into the Therapy of Pateints > 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
Aims: The purpose of this study is to examine the effects of standard chemotherapy regimen for AML that combines and experimental agent, sorafenib with the drugs daunoribicin and cytarabine. Approximately one in four patients with AML have a mutation in the leukemia cells in a gene called FLT3. This mutation may help the leukemia cells grow and survive. Sorafenib inhibits the effects of this abnormal FLT3 gene. Combining sorafenib with a standard chemotherapy regimin may be more effective than the standard chemotherapy regimine alone.
Diagnosis: Acute Myeloid Leukemia
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH12-416
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768.
Open to Enrollment: Yes